Search results
Results from the WOW.Com Content Network
Intercept (ICPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes. Intercept (ICPT) Catches Eye: Stock Jumps 8.4% Skip to main content
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced a summary of its actions to improve its capital position, including the recently announced private repurchases of senior secured convertible ...
Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) completed the sale of its international business for $405 million in upfront consideration. The company held a pre-submission meeting with FDA in July ...
For premium support please call: 800-290-4726 more ways to reach us
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary ...
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ: ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA ...